GoKawiilLife Biosciences begins human trial of Yuancheng Lu's age-reversal gene therapy for glaucoma
Geneticist Yuancheng Lu, working in David Sinclair's Harvard lab, developed a reprogramming gene therapy in 2018 that regenerated crushed optic nerves in mice and restored their vision. That same therapy, now called ER-100, has been adapted for humans by the startup Life Biosciences, which in June injected it into the eye of a glaucoma patient as part of a clinical trial.